Bupropion Mediated Effects on Depression, Attention Deficit Hyperactivity Disorder, and Smoking Cessation
Bupropion had been in use since the late 1980s as an unconventional treatment for depression. Unlike other antidepressants, bupropion has no serotonergic activity and inhibits the reuptake of norepinephrine and dopamine. The drug has been used to treat depression, Attention Deficit Hyperactivity Disorder (ADHD), and smoking cessation. This investigation reviews the pharmacokinetic and pharmacodynamic effects of bupropion and its mechanisms of action and interactions with other drugs. We evaluated the efficacy of major on and off-label uses of bupropion, focusing on the indications, benefits, and adverse effects. Our review demonstrates that bupropion is superior to placebo and non-inferior to SSRIs such as escitalopram in treating major depressive disorder. More research is needed to determine positive patient-centered outcomes such as increases in quality of life. In the case of ADHD, the evidence for efficacy is mixed with poorly conducted randomized clinical trials, small sample sizes, and a lack of long-term assessments. The same is true in the case of bipolar disorder in which there is still limited and controversial data available on bupropion’s safety and efficacy. In the case of smoking cessation, bupropion is found to be an effective anti-smoking drug with synergistic benefits when used as a combination therapy. We conclude that bupropion has the potential to provide benefit for a subset of patients who do not tolerate other typical antidepressants or anti-smoking therapies or for those whose treatment goals align with bupropion’s unique side effect profile, such as smokers who wish to quit and lose weight. Additional research is needed to determine the drug’s full clinical potential, particularly in the areas of adolescent depression and combination therapy with varenicline or dextromethorphan. Clinicians should use this review to understand the varied uses of the drug and identify the situations and patient populations in which bupropion can lend its greatest benefit.
1. Fava M, Rush AJ, Thase ME, et al. 15 Years of Clinical Experience With Bupropion HCl: From Bupropion to Bupropion SR to Bupropion XL. Prim Care Companion CNS Disord. 2005;7(3). doi:10.4088/pcc.v07n0305
2. Stahl SM, Pradko J, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion CNS Disord. 2004;6(4):159-166. doi:10.4088/pcc.v06n0403
3. Soroko FE, Maxwell RA. The pharmacologic basis for therapeutic interest in bupropion. J Clin Psychiatry. 1983;44(5 Pt 2):67-73.
4. Ferry L, Johnston JA. Efficacy and safety of bupropion SR for smoking cessation: data from clinical trials and five years of postmarketing experience. Int J Clin Pract. 2003;57(3):224-230. doi:10.1111/j.1742-1241.2003.tb10468.x
5. Gardner EA. Effects of bupropion on weight in patients intolerant to previous antidepressants. Eff Bupropion Weight Patients Intoler Previous Antidepressants. 1984;35(2):188-199.
6. Wender PH, Reimherr FW. Bupropion treatment of attention-deficit hyperactivity disorder in adults. Am J Psychiatry. 1990;147(8):1018-1020. doi:10.1176/ajp.147.8.1018
7. GlaxoSmithKline to Plead Guilty and Pay $3 Billion to Resolve Fraud Allegations and Failure to Report Safety Data. Published July 2, 2012. Accessed March 22, 2023. https://www.justice.gov/opa/pr/glaxosmithkline-plead-guilty-and-pay-3-billion-resolve-fraud-allegations-and-failure-report
8. Findlay JWA, Van Wyck Fleet J, Smith PG, et al. Pharmacokinetics of bupropion, a novel antidepressant agent, following oral administration to healthy subjects. Eur J Clin Pharmacol. 1981;21(2):127-135. doi:10.1007/bf00637513
9. Schroeder DH. Metabolism and kinetics of bupropion. J Clin Psychiatry. 1983;44(5 Pt 2):79-81.
10. Foley KF, DeSanty KP, Kast RE. Bupropion: pharmacology and therapeutic applications. Expert Rev Neurother. 2006;6(9):1249-1265. doi:10.1586/14737175.6.9.1249
11. Connarn JN, Flowers S, Kelly M, et al. Pharmacokinetics and Pharmacogenomics of Bupropion in Three Different Formulations with Different Release Kinetics in Healthy Human Volunteers. AAPS J. 2017;19(5):1513-1522. doi:10.1208/s12248-017-0102-8
12. Jefferson JW, Pradko JF, Muir KT. Bupropion for major depressive disorder: Pharmacokinetic and formulation considerations. Clin Ther. 2005;27(11):1685-1695. doi:10.1016/j.clinthera.2005.11.011
13. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54(8):800-805. doi:10.1016/s0006-3223(02)01834-6
14. Wang X, Vernikovskaya DI, Abdelrahman DR, Hankins GDV, Ahmed MS, Nanovskaya TN. Simultaneous quantitative determination of bupropion and its three major metabolites in human umbilical cord plasma and placental tissue using high-performance liquid chromatography-tandem mass spectrometry. J Pharm Biomed Anal. 2012;70:320-329. doi:10.1016/j.jpba.2012.05.008
15. Hesse LM, Venkatakrishnan K, Court MH, et al. CYP2B6 Mediates the In Vitro Hydroxylation of Bupropion: Potential Drug Interactions with Other Antidepressants. Drug Metab Dispos. 2000;28(10):1176.
16. Faucette SR, Hawke RL, Shord SS, Lecluyse EL, Lindley CM. Evaluation of the Contribution of Cytochrome P450 3A4 to Human Liver Microsomal Bupropion Hydroxylation. Drug Metab Dispos. 2001;29(8):1123.
17. Faucette SR, Hawke RL, Lecluyse EL, et al. Validation of Bupropion Hydroxylation as a Selective Marker of Human Cytochrome P450 2B6 Catalytic Activity. Drug Metab Dispos. 2000;28(10):1222.
18. Sager JE, Choiniere JR, Chang J, Stephenson-Famy A, Nelson WL, Isoherranen N. Identification and Structural Characterization of Three New Metabolites of Bupropion in Humans. ACS Med Chem Lett. 2016;7(8):791-796. doi:10.1021/acsmedchemlett.6b00189
19. Kirchheiner J, Klein C, Meineke I, et al. Bupropion and 4-OH-bupropion pharmacokinetics in relation to genetic polymorphisms in CYP2B6. Pharmacogenetics. 2003;13(10):619-626. doi:10.1097/00008571-200310000-00005
20. Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51(3):293-313. doi:10.1080/03602532.2019.1620763
21. Sager JE, Tripathy S, Price LSL, et al. In vitro to in vivo extrapolation of the complex drug-drug interaction of bupropion and its metabolites with CYP2D6; simultaneous reversible inhibition and CYP2D6 downregulation. Biochem Pharmacol. 2017;123:85-96. doi:10.1016/j.bcp.2016.11.007
22. Taylor C, Crosby I, Yip V, Maguire P, Pirmohamed M, Turner RM. A Review of the Important Role of CYP2D6 in Pharmacogenomics. Genes. 2020;11(11):1295. doi:10.3390/genes11111295
23. Shin J, Hills NK, Finley PR. Combining Antidepressants with β-Blockers: Evidence of a Clinically Significant CYP2D6 Drug Interaction. Pharmacotherapy. 2020;40(6):507-516. doi:10.1002/phar.2406
24. Dahl ML, Leander K, Vikstrom M, et al. CYP2D6-inhibiting drugs and risk of fall injuries after newly initiated antidepressant and antipsychotic therapy in a Swedish, register-based case-crossover study. Sci Rep. 2021;11(1):5796. doi:10.1038/s41598-021-85022-x
25. Pierre JM, Gitlin MJ. Bupropion-Tranylcypromine Combination for Treatment-Refractory Depression. J Clin Psychiatry. 2000;61(6):450-451. doi:10.4088/jcp.v61n0610h
26. Quante A, Zeugmann S. Tranylcypromine and Bupropion Combination Therapy in Treatment-Resistant Major Depression: A Report of 2 Cases. J Clin Psychopharmacol. 2012;32(4):572-574. doi:10.1097/jcp.0b013e31825de0a7
27. Calvi A, Fischetti I, Verzicco I, et al. Antidepressant Drugs Effects on Blood Pressure. Front Cardiovasc Med. 2021;8:704281. doi:10.3389/fcvm.2021.704281
28. Andrade C. Breast Cancer and Antidepressant Use. J Clin Psychiatry. 2012;73(09):e1156-e1157. doi:10.4088/jcp.12f08054
29. Bradbury M, Hutton B, Beltran-Bless AA, et al. Time to Update Evidence-Based Guideline Recommendations About Concurrent Tamoxifen and Antidepressant Use? A Systematic Review. Clin Breast Cancer. 2022;22(3):e362-e373. doi:10.1016/j.clbc.2021.10.003
30. Shalabi AR, Walther D, Baumann MH, Glennon RA. Deconstructed Analogues of Bupropion Reveal Structural Requirements for Transporter Inhibition versus Substrate-Induced Neurotransmitter Release. ACS Chem Neurosci. 2017;8(6):1397-1403. doi:10.1021/acschemneuro.7b00055
31. Pakdel FG, Amirabadi S, Naderi S, et al. Effects of Acute Intracerebroventricular Microinfusions of Bupropion on Background Spike Activity of Locus Coeruleus Neurons in Rats. Neurophysiology. 2014;46(4):316-322. doi:10.1007/s11062-014-9450-5
32. Sidhpura N, Redfern P, Rowley H, Heal D, Wonnacott S. Comparison of the effects of bupropion and nicotine on locomotor activation and dopamine release in vivo. Biochem Pharmacol. 2007;74(8):1292-1298. doi:10.1016/j.bcp.2007.06.025
33. Slemmer JE, Martin BR, Damaj MI. Bupropion Is a Nicotinic Antagonist. J Pharmacol Exp Ther. 2000;295(1):321.
34. Aubin HJ. Tolerability and Safety of Sustained-Release Bupropion in the Management of Smoking Cessation. Drugs. 2002;62(Supplement 2):45-52. doi:10.2165/00003495-200262002-00005
35. Pesola GR, Avasarala J. Bupropion seizure proportion among new-onset generalized seizures and drug related seizures presenting to an emergency department. J Emerg Med. 2002;22(3):235-239. doi:10.1016/s0736-4679(01)00474-7
36. Beyens MN, Guy C, Mounier G, Laporte S, Ollagnier M. Serious Adverse Reactions of Bupropion for Smoking Cessation: Analysis of the French Pharmacovigilance Database from 2001 to 2004. Drug Saf. 2008;31(11):1017-1026. doi:10.2165/00002018-200831110-00006
37. Shepherd G, Velez LI, Keyes DC. Intentional bupropion overdoses. J Emerg Med. 2004;27(2):147-151. doi:10.1016/j.jemermed.2004.02.017
38. Munhoz RP. Serotonin Syndrome Induced by a Combination of Bupropion and SSRIs. Clin Neuropharmacol. 2004;27(5):219-222. doi:10.1097/01.wnf.0000142754.46045.8c
39. Thorpe EL, Pizon AF, Lynch MJ, Boyer J. Bupropion Induced Serotonin Syndrome: A Case Report. J Med Toxicol. 2010;6(2):168-171. doi:10.1007/s13181-010-0021-x
40. Sidlak AM, Koivisto KO, Marino RT, Abesamis MG. Serotonin toxicity from isolated bupropion overdoses. Clin Toxicol. 2020;58(12):1347-1349. doi:10.1080/15563650.2020.1742920
41. Caillier B, Pilote S, Castonguay A, et al. QRS widening and QT prolongation under bupropion: a unique cardiac electrophysiological profile. Fundam Clin Pharmacol. 2011;26(5):599-608. doi:10.1111/j.1472-8206.2011.00953.x
42. Stassinos GL, Klein-Schwartz W. Bupropion “Abuse” Reported to US Poison Centers. J Addict Med. 2016;10(5):357-362. doi:10.1097/adm.0000000000000249
43. Stahl SM, Pradko J, Haight BR, Modell JG, Rockett CB, Learned-Coughlin S. A Review of the Neuropharmacology of Bupropion, a Dual Norepinephrine and Dopamine Reuptake Inhibitor. Prim Care Companion CNS Disord. 2004;6(4):159-166. doi:10.4088/pcc.v06n0403
44. Dhillon S, Yang LPH, Curran MP. Bupropion. Drugs. 2008;68(5):653-689. doi:10.2165/00003495-200868050-00011
45. Patel K, Allen S, Haque MN, Angelescu I, Baumeister D, Tracy DK. Bupropion: a systematic review and meta-analysis of effectiveness as an antidepressant. Ther Adv Psychopharmacol. 2016;6(2):99-144. doi:10.1177/2045125316629071
46. Kishi T, Ikuta T, Sakuma K, et al. Antidepressants for the treatment of adults with major depressive disorder in the maintenance phase: a systematic review and network meta-analysis. Mol Psychiatry. 2023;28(1):402-409. doi:10.1038/s41380-022-01824-z
47. Weihs KL, Houser TL, Batey SR, et al. Continuation phase treatment with bupropion SR effectively decreases the risk for relapse of depression. Biol Psychiatry. 2002;51(9):753-761. doi:10.1016/s0006-3223(01)01317-8
48. Lee SY, Wang LJ, Yang YH, Hsu CW. The comparative effectiveness of antidepressants for youths with major depressive disorder: a nationwide population-based study in Taiwan. Ther Adv Chronic Dis. 2022;13:20406223221098110. doi:10.1177/20406223221098114
49. Hsu CW, Tseng WT, Wang LJ, Yang YH, Kao HY, Lin PY. Comparative effectiveness of antidepressants on geriatric depression: Real-world evidence from a population-based study. JAffect Disord. 2022;296:609-615. doi:10.1016/j.jad.2021.10.009
50. Henssler J, Alexander D, Schwarzer G, Bschor T, Baethge C. Combining Antidepressants vs Antidepressant Monotherapy for Treatment of Patients With Acute Depression: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2022;79(4):300-312. doi:10.1001/jamapsychiatry.2021.4313
51. Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022;179(7):490-499. doi:10.1176/appi.ajp.21080800
52. Pacchiarotti I, Bond DJ, Baldessarini RJ, et al. The International Society for Bipolar Disorders (ISBD) Task Force Report on Antidepressant Use in Bipolar Disorders. Am J Psychiatry. 2013;170(11):1249-1262. doi:10.1176/appi.ajp.2013.13020185
53. Koshino Y, Bahk WM, Sakai H, Kobayashi T. The efficacy and safety of bupropion sustained-release formulation for the treatment of major depressive disorder: a multi-center, randomized, double-blind, placebo-controlled study in Asian patients. Neuropsychiatr Dis Treat. 2013;9:1273-1280. doi:10.2147/ndt.s48158
54. Tabuteau H, Jones A, Anderson A, Jacobson M, Iosifescu DV. Effect of AXS-05 (Dextromethorphan-Bupropion) in Major Depressive Disorder: A Randomized Double-Blind Controlled Trial. Am J Psychiatry. 2022;179(7):490-499. doi:10.1176/appi.ajp.21080800
55. Iosifescu DV, Jones A, O'Gorman C, et al. Efficacy and Safety of AXS-05 (Dextromethorphan-Bupropion) in Patients With Major Depressive Disorder: A Phase 3 Randomized Clinical Trial (GEMINI). J Clin Psychiatry. 2022;83(4):21-14345. doi:10.4088/jcp.21m14345
56. Shen Y, Zhao Q, Yu Y, et al. Efficacy and safety of bupropion hydrochloride extended-release versus escitalopram oxalate in Chinese patients with major depressive disorder: Results from a randomized, double-blind, non-inferiority trial. J Affect Disord. 2019;257:143-149. doi:10.1016/j.jad.2019.07.023
57. Verbeeck W, Bekkering GE, Van den Noortgate W, Kramers C. Bupropion for attention deficit hyperactivity disorder (ADHD) in adults. Cochrane Database Syst Rev. 2017;2017(10):CD009504. doi:10.1002/14651858.cd009504.pub2
58. Ng QX. A Systematic Review of the Use of Bupropion for Attention-Deficit/Hyperactivity Disorder in Children and Adolescents. J Child Adolesc Psychopharmacol. 2017;27(2):112-116. doi:10.1089/cap.2016.0124
59. Tripp G, Wickens JR. Neurobiology of ADHD. Neuropharmacology. 2009;57(7-8):579-589. doi:10.1016/j.neuropharm.2009.07.026
60. Costa R, Oliveira NG, Dinis-Oliveira RJ. Pharmacokinetic and pharmacodynamic of bupropion: integrative overview of relevant clinical and forensic aspects. Drug Metab Rev. 2019;51(3):293-313. doi:10.1080/03602532.2019.1620763
61. Learned-Coughlin SM, Bergstrom M, Savitcheva I, Ascher J, Schmith VD, Langstrom B. In vivo activity of bupropion at the human dopamine transporter as measured by positron emission tomography. Biol Psychiatry. 2003;54(8):800-805. doi:10.1016/s0006-3223(02)01834-6
62. Maneeton N, Maneeton B, Srissurapanont M, Martin SD. Bupropion for adults with attention-deficit hyperactivity disorder: meta-analysis of randomized, placebo-controlled trials. Psychiatry Clin Neurosci. 2011;65(7):611-617. doi:10.1111/j.1440-1819.2011.02264.x
63. Li Y, Gao J, He S, Zhang Y, Wang Q. An Evaluation on the Efficacy and Safety of Treatments for Attention Deficit Hyperactivity Disorder in Children and Adolescents: a Comparison of Multiple Treatments. Mol Neurobiol. 2017;54(9):6655-6669. doi:10.1007/s12035-016-0179-6
64. Cortese S, Adamo N, Del Giovane C, et al. Comparative efficacy and tolerability of medications for attention-deficit hyperactivity disorder in children, adolescents, and adults: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727-738. doi:10.1016/s2215-0366(18)30269-4
65. Nazarova VA, Sokolov AV, Chubarev VN, Tarasov VV, Schioth HB. Treatment of ADHD: Drugs, psychological therapies, devices, complementary and alternative methods as well as the trends in clinical trials. Front Pharmacol. 2022;13:1066988. doi:10.3389/fphar.2022.1066988
66. Catalá-López F, Hutton B, Núnez-Beltrán A, et al. The pharmacological and non-pharmacological treatment of attention deficit hyperactivity disorder in children and adolescents: A systematic review with network meta-analyses of randomised trials. PloS One. 2017;12(7):e0180355. doi:10.1371/journal.pone.0180355
67. Moriyama TS, Polanczyk GV, Terzi FS, Faria KM, Rohde LA. Psychopharmacology and psychotherapy for the treatment of adults with ADHD-a systematic review of available meta-analyses. CNS Spectr. 2013;18(6):296-306. doi:10.1017/s109285291300031x
68. Asherson P, Bushe C, Saylor K, Tanaka Y, Deberdt W, Upadhyaya H. Efficacy of atomoxetine in adults with attention deficit hyperactivity disorder: an integrated analysis of the complete database of multicenter placebo-controlled trials. J Psychopharmacol. 2014;28(9):837-846. doi:10.1177/0269881114542453
69. Stuhec M, Munda B, Svab V, Locatelli I. Comparative efficacy and acceptability of atomoxetine, lisdexamfetamine, bupropion and methylphenidate in treatment of attention deficit hyperactivity disorder in children and adolescents: a meta-analysis with focus on bupropion. J Affect Disord. 2015;178:149-159. doi:10.1016/j.jad.2015.03.006
70. McCabe DJ, McGillis E, Willenbring BA. The Timing of Clinical Effects of Bupropion Misuse Via Insufflation Reported to a Regional Poison Center. J Emerg Med. 2022;62(2):175-181. doi:10.1016/j.jemermed.2021.07.052
71. Tiwari RK, Sharma V, Pandey RK, Shukla SS. Nicotine Addiction: Neurobiology and Mechanism. J Pharmacopuncture. 2020;23(1):1-7. doi:10.3831/kpi.2020.23.001
72. Picciotto MR, Kenny PJ. Mechanisms of Nicotine Addiction. Cold Spring Harb Perspect Med. 2021;11(5):a039610. doi:10.1101/cshperspect.a039610
73. Pontieri FE, Tanda G, Orzi F, Di Chiara G. Effects of nicotine on the nucleus accumbens and similarity to those of addictive drugs. Nature. 1996;382(6588):255-257. doi:10.1038/382255a0
74. Hays JT, Hurt RD, Rigotti NA, et al. Sustained-release bupropion for pharmacologic relapse prevention after smoking cessation. A randomized, controlled trial. Ann Intern Med. 2001;135(6):423-433. doi:10.7326/0003-4819-135-6-200109180-00011
75. Hughes J. Depression during tobacco abstinence. Nicotine Tob Res. 2007;9(4):443-446. doi:10.1080/14622200701243185
76. Giulietti F, Filipponi A, Rosettani G, et al. Pharmacological Approach to Smoking Cessation: An Updated Review for Daily Clinical Practice. High Blood Press Cardiovasc Prev. 2020;27(5):349-362. doi:10.1007/s40292-020-00396-9
77. Huecker MR, Smiley A, Saadabadi A. Bupropion. In: StatPearls. StatPearls Publishing; 2022. Accessed January 30, 2023. http://www.ncbi.nlm.nih.gov/books/NBK470212/
78. Warner C, Shoaib M. How does bupropion work as a smoking cessation aid? Addict Biol. 2005;10(3):219-231. doi:10.1080/13556210500222670
79. Cahill K, Stevens S, Perera R, Lancaster T. Pharmacological interventions for smoking cessation: an overview and network meta-analysis. Cochrane Database Syst Rev. 2013;2013(5):CD009329. doi:10.1002/14651858.cd009329.pub2
80. Son JW, Kim S. Comprehensive Review of Current and Upcoming Anti-Obesity Drugs. Diabetes Metab J. 2020;44(6):802-818. doi:10.4093/dmj.2020.0258
81. Wang GJ, Volkow ND, Logan J, et al. Brain dopamine and obesity. Lancet. 2001;357(9253):354-357. doi:10.1016/s0140-6736(00)03643-6
82. Patnode CD, Henderson JT, Coppola EL, Melnikov J, Durbin S, Thomas RG. Interventions for Tobacco Cessation in Adults, Including Pregnant Persons: Updated Evidence Report and Systematic Review for the US Preventive Services Task Force. JAMA. 2021;325(3):280-298. doi:10.1001/jama.2020.23541
83. Rigotti NA, Kruse GR, Livingstone-Banks J, Hartmann-Boyce J. Treatment of Tobacco Smoking: A Review. JAMA. 2022;327(6):566-577. doi:10.1001/jama.2022.0395
84. Yan T, Goldman RD. Bupropion for smoking cessation in adolescents. Can Fam Physician. 2021;67(10):743-745. doi:10.46747/cfp.6710743
85. Kranzler HR, Washio Y, Zindel LR, et al. Placebo-controlled trial of bupropion for smoking cessation in pregnant women. Am J Obstet Gynecol MFM. 2021;3(6):100315. doi:10.1016/j.ajogmf.2021.100315
86. Weinberger AH, Bandiera FC, Leventhal AM, et al. Socioeconomic Disparities in Smoking Among U.S. Adults With Depression, 2005-2014. Am J Prev Med. 2018;54(6):765-775. doi:10.1016/j.amepre.2018.02.008
87. Cinciripini PM, Kypriotakis G, Green C, et al. The effects of varenicline, bupropion, nicotine patch, and placebo on smoking cessation among smokers with major depression: A randomized clinical trial. Depress Anxiety. 2022;39(5):429-440. doi:10.1002/d a.23259
88. Jordan CJ, Xi ZX. Discovery and development of varenicline for smoking cessation. Expert Opin Drug Discov. 2018;13(7):671-683. doi:10.1080/17460441.2018.1458090
89. Coe JW, Brooks PR, Vetelino MG, et al. Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation. J Med Chem. 2005;48(10):3474-3477. doi:10.1021/jm050069n
90. Guo K, Wang S, Shang X, et al. The effect of Varenicline and Bupropion on smoking cessation: A network meta-analysis of 20 randomized controlled trials. Addict Behav. 2022;131:107329. doi:10.1016/j.addbeh.2022.107329
91. Vogeler T, McClain C, Evoy KE. Combination bupropion SR and varenicline for smoking cessation: a systematic review. Am J Drug Alcohol Abuse. 2016;42(2):129-139. doi:10.3109/00952990.2015.1117480
92. Zaso MJ, Hendershot CS. Effects of varenicline and bupropion on laboratory smoking outcomes: Meta-analysis of randomized, placebo-controlled human laboratory studies. Addict Biol. 2022;27(5):e13218. doi:10.1111/adb.13218
93. Zhong Z, Zhao S, Zhao Y, Xia S. Combination therapy of varenicline and bupropion in smoking cessation: A meta-analysis of the randomized controlled trials. Compr Psychiatry. 2019;95:152125. doi:10.1016/j.comppsych.2019.152125
94. Karadogan D, Onal O, Sahin DS, Kanbay Y, Alp S, Sahin U. Treatment adherence and short-term outcomes of smoking cessation outpatient clinic patients. Tob Induc Dis. 2018;16:38. doi:10.18332/tid/94212
95. Cahill K, Lindson-Hawley N, Thomas KH, Fanshawe TR, Lancaster T. Nicotine receptor partial agonists for smoking cessation. Cochrane Database Syst Rev. 2016;2016(5):CD006103. doi:10.1002/14651858.cd006103.pub7